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Background: Noncompliance (NC) is probably the major cause of clopidogrel “resistance” (CR). However, NC is difficult to prove without 
confirming that the drug has been administered. Therefore, detection of plasma clopidogrel and/or metabolite(s) as the reliable objective method to 
confirm NC is important. We sought to correlate the inhibition of platelet aggregation (IPA) with plasma levels of unchanged clopidogrel (UC), active 
thiol metabolite (ATM), and inactive carboxyl metabolite (ICM) in a large cohort of patients with coronary artery disease (CAD) and ischemic stroke 
(IS) treated with clopidogrel.
Methods: Secondary post-hoc analyses of IPA and plasma UC, ATM, and ICM in a dataset consisting of presumably compliant patients with CAD 
(n=422) and IS (n=209).
Results: Overall NC rate was 22% (n=138), while NC risks were significantly higher in IS patients (n=79, or 38%) when compared to patients with 
CAD (14%; n=59; p=0.001). Only ICM (19,154±7,228ng/ml) was suitable for detecting NC, while UC (15.2±9.4ng/ml), and ATM (8.1±3.7ng/ml) in 
most cases are barely detectable, and diminish over time in the stored samples. The best correlation with IPA (r2 =0.847) was observed for active 
metabolite, followed by unchanged clopidogrel (r2 =0.602), and finally inactive metabolite (r2 =0.529). The predictive value for NC was also high for 
inactive metabolite (c-statistic=0.911).
Conclusion: Therapy with clopidogrel is associated with double digit underestimated NC risks, especially in stroke survivors, supporting the 
hypothesis that lack of IPA, and CR are attributed to hidden NC. Plasma ICM, but not UC, or ATM is a useful marker to monitor compliance to 
clopidogrel in registries and clinical trials.
